1 January 2021 in Medical Image Analysis
3 September 2018 in Acta Orthopaedica
(2018). Surgery guided by mixed reality: presentation of a proof of concept. Acta Orthopaedica: Vol. 89, No. 5, pp. 480-483.
1 October 2021 in Radiology
Using reverse transcription–polymerase chain reaction as the reference standard in 10 735 patients with suspected COVID-19 pneumonia, CT was 80% accurate and was also predictive of death or need fo... Background There are conflicting data regarding the diagnostic performance of chest CT for COVID-19 pneumonia. Disease extent at CT has been reported to influence prognosis. Purpose To create a lar...
1 February 2021 in Radiology
Background The role and performance of chest CT in the diagnosis of the coronavirus disease 2019 (COVID-19) pandemic remains under active investigation. Purpose To evaluate the French national expe...
12 February 2016 in European Radiology
CRChristine Rousset-Jablonski
Christine Rousset-Jablonski
+3
1 June 2020 in JHEP Reports
The goal of assessing tumour response on imaging is to identify patients who are likely to benefit - or not - from anticancer treatment, especially in relation to survival. The World Health Organization was the first to develop assessment criteria. This early score, which assessed tumour burden by standardising lesion size measurements, laid the groundwork for many of the criteria that followed. This was then improved by the Response Evaluation Criteria in Solid Tumours (RECIST) which was quickly adopted by the oncology community. At the same time, many interventional oncology treatments were developed to target specific features of liver tumours that result in significant changes in tumours but have little effect on tumour size. New criteria focusing on the viable part of tumours were therefore designed to provide more appropriate feedback to guide patient management. Targeted therapy has resulted in a breakthrough that challenges conventional response criteria due to the non-linear relationship between response and tumour size, requiring the development of methods that emphasize the appearance of tumours. More recently, research into functional and quantitative imaging has created new opportunities in liver imaging. These results have suggested that certain parameters could serve as early predictors of response or could predict later tumour response at baseline. These approaches have now been extended by machine learning and deep learning. This clinical review focuses on the progress made in the evaluation of liver tumours on imaging, discussing the rationale for this approach, addressing challenges and controversies in the field, and suggesting possible future developments.